Skip to content

Mass balance of albumin in sepsis

An observational pilot study of albumin kinetics as assessed by mass balance in patients with severe sepsis/septic shock

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12616001505493
Acronym
Albumin 6B
Enrollment
20
Registered
2016-10-31
Start date
2017-02-20
Completion date
2018-03-30
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Septic shock is a leading cause of hospital mortality. Manifest circulatory instability characterizes septic shock, and intravenous infusion of fluids is a cornerstone in the treatment, to maintain blood pressure and blood flow to vital organs. However, the fluid will to some part leak into the interstitial space causing edema, and the size of this weight gain is correlated to mortality and morbidity. Plasma albumin (P-alb) is a negative phase reactant. The effect of albumin is reported to be no more harmful than that of normal saline, but the volume sparing effect of albumin is small in ICU patients. An increased rate of leakage of albumin from the vascular system in septic patients has been demonstrated, but the return of proteins and fluid by the lymphatic system is impossible to measure directly. However, the combined effect of leakage and return can be assessed by albumin mass balance. Thus, the relationship between the negative phase reactant plasma albumin and the amount of albumin accumulating outside the blood vessels can be estimated and increase our knowledge of our present fluid treatment effects. We have previously demonstrated albumin leakage from the blood stream in major abdominal surgery by albumin mass balance describing the relationship between albumin within and outside the vascular system perioperatively. We want to apply the same technique to septic ICU patients. In this observational study we investigate patients with severe sepsis/septic shock. We will collect blood samples during the first 24 hrs in ICU and quantify cumulative albumin shift, i.e. the amount of albumin accumulating supposedly in the extracellular space. We will also characterize markers of endothelial injury (components of the glycocalyx), markers of inflammations (interleukins) and indices of volume status (fluid balance, weight gain, rate of infusions). Finally all these indices will be correlated to albumin kinetic parameters to generate hypothesis for future studies. The overall aim of our research program is to define the role of albumin in modern fluid therapy. This study is an important step to understand the effects of our present fluid strategy on the vasculature, and to generate new hypotheses on the mechanisms. Future studies will depend on these results.

Interventions

Patients with severe sepsis/septic shock, admitted to the ICU, will be studied during 24 hrs. Blood will be sampled repeatedly (at arrival to ICU, at 1, 2, 4, 8-12 and 24 hrs after the first sample) for assessment of albumin, markers of endothelial injury and markers of inflammation. Samples will also be taken from any patient excretions and from intravenously infused blood products. Baseline plasma volume will be calculated by anthropometry. The sum of all blood samples will not exceed 20 ml.

Sponsors

Ake Norberg
Lead SponsorIndividual

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients admitted to ICU for severe sepsis/septic shock

Exclusion criteria

Absence of written informed consent Death or transport to another hospital

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026